Overview

ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure

Status:
Not yet recruiting
Trial end date:
2024-11-12
Target enrollment:
Participant gender:
Summary
This study is a prospective monocentric, randomized, double-blind, placebo-controlled, crossover clinical trial to assess the efficacy of Sacubitril/Valsartan over placebo in improving exercise capacity and neurohormonal activation in adults with moderate to severe systemic RV dysfunction and NYHA class II or III symptoms.
Phase:
N/A
Details
Lead Sponsor:
Montreal Heart Institute
Collaborator:
Novartis Pharmaceuticals
Treatments:
Valsartan